Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioject gets second deal with Amgen:

This article was originally published in Clinica

Executive Summary

Bioject Medical Technologies has formed a second agreement with Amgen for Bioject's needle-free injection system for certain of Amgen's therapeutics. Bioject will get $1 million upfront, as well as development milestones and other payments. Amgen will get exclusive rights to the Portland, Oregon-based company's modified B2000 needle-free system. Under the terms of the new contract, Amgen's potential use of the needle-free systems is expanded. It also includes product licensing and commercial supply terms. The initial contract was signed in March 2000 and covered Bioject's Iject systems.

Topics

UsernamePublicRestriction

Register

MT074478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel